BC
AGIO icon

Bridgefront Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Bridgefront Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
31,097
+24,546
+375% +$745K 0.3% 95
2026
Q1 		$222K Sell
6,551
-6,098
-48% -$173K 0.06% 462
2025
Q4 		$344K Buy
+12,649
New +$444K 0.09% 347
2024
Q3 		– Sell
-4,965
Closed -$214K – 510
2024
Q2 		$214K Buy
+4,965
New +$179K 0.09% 392
2021
Q1 		– Sell
-6,059
Closed -$263K – 650
2020
Q4 		$263K Buy
+6,059
New +$240K 0.09% 423

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Bridgefront Capital's AGIO Position: Q2 2026 in Review

Bridgefront Capital increased its Agios Pharmaceuticals (AGIO) stake by 375% in Q2 2026, buying an estimated $745K and bringing the position to 31,097 shares worth $1.15M. The position accounts for 0.3% of the portfolio, ranked #95.

Bridgefront Capital first reported a position in AGIO in Q4 2020 and has held it in 5 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Bridgefront Capital held 31,097 shares of Agios Pharmaceuticals worth $1.15M as of Q2 2026.
  • Bridgefront Capital bought 24,546 Agios Pharmaceuticals shares in Q2 2026, an estimated $745K.
  • Agios Pharmaceuticals made up 0.3% of Bridgefront Capital's portfolio in Q2 2026, its #95 holding.
  • Bridgefront Capital first reported a position in Agios Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.